Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service breast reconstruction cases in Washington: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (125 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 535 | 37% |
| 2020 | 2 | 490 | 40% |
| 2021 | 3 | 417 | 43% |
| 2022 | 1 | 313 | 46% |
| 2023 | 0 | 238 | 50% |
| 2024 | 0 | 328 | 54% |
| 2025 from claims | – | 320 259–376 | 54% |
| 2026 forecast | – | 324 254–407 | 54% |
| 2027 forecast | – | 325 241–429 | 55% |
| 2028 forecast | – | 325 230–449 | 56% |
| 2029 forecast | – | 325 221–466 | 57% |
| 2030 forecast | – | 325 213–482 | 57% |
Implant- and flap-based reconstruction; ADM and expander call point. Professional codes (what the surgeon bills): CPT 19357, 19340, 19342, 19364, 19380.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 10% inpatient hospital, 67% hospital outpatient, 22% surgery center. The share outside the hospital has moved +27 pts since 2019, so more of this market is decided in surgery centers and offices each year.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 12 | 1,522−3.4%/yr | −3.4%/yr | 0.5 | 0% | 2,040 in 2030+5%/yr |
| Arizona | 2 | 390−7.9%/yr | −7.9%/yr | 0.5 | 11% | 540 in 2030+5.6%/yr |
| Colorado | 0 | 223−9.1%/yr | −9.1%/yr | 0.5 | 0% | 230 in 2030+0.5%/yr |
| Utah | 0 | 128−2.1%/yr | −2.1%/yr | 0.6 | 0% | 650 in 2030+31%/yr |
| Oregon | 0 | 119−15%/yr | −15%/yr | 0.3 | 48% | 130 in 2030+1.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 50 | 4,184−4.3%/yr | −4.3%/yr | 5.81.0× | 11% | 4,250 in 2030+0.3%/yr |
| Cholecystectomy & appendectomy | 31 | 2,636−5.6%/yr | −5.6%/yr | 3.50.9× | 2% | 2,630 in 20300%/yr |
| Colorectal resection | 4 | 1,073−5.1%/yr | −5.1%/yr | 1.41.0× | 0% | 1,020 in 2030−0.9%/yr |
| Antireflux & hiatal hernia surgery | 11 | 544+0.4%/yr | +0.4%/yr | 0.71.0× | 0% | 760 in 2030+5.7%/yr |
| Bariatric surgery | 0 | 101−19%/yr | −19%/yr | 0.10.8× | 0% | 20 in 2030−23%/yr |
Breast reconstruction in every state, and its device makers · Every procedure market in Washington · Every state · Compare with California
Abbvie leads with 87% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 9 companies reported engagement with Washington’s surgeons worth $159K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.